CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Zendy

Jun Li | Zendy; Xi Zhang | Zendy; Jiang F. Zhong | Zendy; Cheng Zhang | Zendy

Open Access

CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author(s) -

Jun Li,

Xi Zhang,

Jiang F. Zhong,

Cheng Zhang

Publication year - 2017

Publication title -

immunotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.127

H-Index - 48

eISSN - 1750-7448

pISSN - 1750-743X

DOI - 10.2217/imt-2017-0072

Subject(s) - chimeric antigen receptor , refractory (planetary science) , hematopoietic stem cell transplantation , medicine , stem cell , immunology , transplantation , t cell , oncology , cancer research , immune system , biology , genetics , astrobiology

Relapsed/refractory acute lymphoblastic leukemia (ALL) has a low remission rate after chemotherapy, a high relapse rate and poor long-term survival even when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed. Chimeric antigen receptors redirected T cells (CAR-T cells) can enhance disease remission with a favorable outcome for relapsed/refractory ALL, though some cases quickly relapsed after CAR-T cell treatment. Thus, treatment with CAR-T cells followed by allo-HSCT may be the best way to treat relapsed/refractory ALL. In this review, we first discuss the different types of CAR-T cells. We then discuss the treatment of relapsed/refractory ALL using only CAR-T cells. Finally, we discuss the use of CAR-T cells, followed by allo-HSCT, for the treatment of relapsed/refractory ALL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research